Skip to main content

Unknown

1
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
2 programs
1
AMG 378Phase 1
AMG 701N/A3 trials
Active Trials
NCT05256446No Longer Available
NCT04998747Withdrawn0Est. Aug 2025
NCT03287908Terminated174Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenAMG 701
AmgenAMG 701

Clinical Trials (3)

Total enrollment: 174 patients across 3 trials

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Start: Aug 2023Est. completion: Aug 20250
Phase 1Withdrawn

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Start: Nov 2017Est. completion: Jun 2023174 patients
Phase 1Terminated

AMG 701 Expanded Access Program

N/ANo Longer Available

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.